Profound Medical Inc. is a commercial‑stage medical technology company headquartered in Mississauga, Ontario, dedicated to advancing care for prostate cancer and benign prostatic hyperplasia (BPH). Its flagship product, TULSA‑PRO®, is an FDA‑cleared, AI‑powered, MRI‑guided robotic ablation system that performs incision‑free prostate tissue ablation with real‑time precision and customizable treatment plans. By integrating cutting‑edge imaging, artificial intelligence, and robotic control, TULSA‑PRO® delivers clinically effective outcomes while preserving patients’ quality of life—setting a new standard in minimally invasive prostate therapy. The platform is fully reimbursable, enabling widespread adoption by clinicians seeking advanced, patient‑centric solutions.
Support the lifecycle of TULSA-PRO implementation at clinical sites, build relationships with healthcare providers and external stakeholders, and execute account-specific strategies to grow program awareness and procedural volume.
Profound Medical Inc. is a commercial‑stage medical technology company headquartered in Mississauga, Ontario, dedicated to advancing care for prostate cancer and benign prostatic hyperplasia (BPH). Its flagship product, TULSA‑PRO®, is an FDA‑cleared, AI‑powered, MRI‑guided robotic ablation system that performs incision‑free prostate tissue ablation with real‑time precision and customizable treatment plans. By integrating cutting‑edge imaging, artificial intelligence, and robotic control, TULSA‑PRO® delivers clinically effective outcomes while preserving patients’ quality of life—setting a new standard in minimally invasive prostate therapy. The platform is fully reimbursable, enabling widespread adoption by clinicians seeking advanced, patient‑centric solutions.
Lakeview Hospital